GENE ONLINE|News &
The Rejuvenated Promise of RNA Therapeutics
The field of RNA therapeutics is a budding one as compared to small molecules or protein therapeutics. Its recent surge must be attributed to the decades of work put into eliminating various drawbacks. “With a number of drugs in late-stage trials, the field is going to take off” says Dr. Judy Lieberman, Professor, Department of Pediatrics, Harvard Medical School. Since 2006, she also serves as an elected member of the Scientific Advisory Board for Alnylam Pharmaceuticals.
It's free! Log in now to read
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
